Perrigo Approved for Generic Luxiq Foam
Perrigo announced that its partner, Cobrek Pharmaceuticals, received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Betamethasone Valerate Foam 0.12%, the generic version Stiefel Laboratories' Luxiq Foam.
Luxiq is a topical steroid indicated for the relief of corticosteroid-responsive skin conditions of the scalp (scalp psoriasis). It contains anti-inflammatory, antipruritic, and vasoconstrictive properties. It is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins.
Betamethasone Valerate Foam 0.12% is expected to commence shipping on January 15, 2013.
For more information call (800) 719-9260 or visit www.perrigo.com.